Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells

ABT‐263 (Navitoclax) is a BH3‐mimetic drugs targeting anti‐apoptotic B‐cell lymphoma‐2 (BCL‐2) family proteins, including BCL‐2, BCL‐xL, and BCL‐w, thereby inducing apoptosis. In small‐cell lung cancer (SCLC) cells, the response to ABT‐263 is associated with the expression of myeloid cell leukemia‐1...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohgino, Keiko, Terai, Hideki, Yasuda, Hiroyuki, Nukaga, Shigenari, Hamamoto, Junko, Tani, Tetsuo, Kuroda, Aoi, Arai, Daisuke, Ishioka, Kota, Masuzawa, Keita, Ikemura, Shinnosuke, Kawada, Ichiro, Naoki, Katsuhiko, Fukunaga, Koichi, Soejima, Kenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Drug Discovery and Delivery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541018/
https://www.ncbi.nlm.nih.gov/pubmed/32687646
http://dx.doi.org/10.1111/cas.14569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541018/
https://www.ncbi.nlm.nih.gov/pubmed/32687646
http://dx.doi.org/10.1111/cas.14569

Ejemplares similares